CD33 and acute myeloid leukemia: In CAR-T cells targeting CD33 for the treatment of AML, scFvs targeting membrane-proximal epitopes of CD33 generated more robust cytotoxicity against low antigen abundance tumors compared to scFvs targeting membrane-distal epitopes [54].